AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update [Yahoo! Finance]
AC Immune SA (ACIU)
Last ac immune sa earnings: 11/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
acimmune.com/en/investors
Company Research
Source: Yahoo! Finance
AC Immune SA AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update Phase 2 interim results suggest treatment with active immunotherapy ACI-7104 may slow the progression of Parkinson's disease NLRP3 inhibitor ACI-19764 Phase 1 trial initiated with first participants dosed Approaching multiple value-inflection points, including interim results of the AD3 cohort in the Phase 2 ABATE trial of ACI-24 in Alzheimer's disease in H1 2026, and full 24-month data from Part 1 of the Phase 2 VacSYn trial of ACI-7104 in Q3 2026 Cash resources of CHF 91.4 million as of December 31, 2025, provide funding to the end of Q3 2027 before any potential milestone payments Lausanne, Switzerland, March 13, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today reported results for the full year ended December 31, 2025, and provided a corporate update. Dr. Andrea Pfeifer,
Show less
Read more
Impact Snapshot
Event Time:
ACIU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACIU alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACIU alerts
High impacting AC Immune SA news events
Weekly update
A roundup of the hottest topics
ACIU
News
- AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PDTM 2026GlobeNewswire
- Is AC Immune (ACIU) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]Yahoo! Finance
- AC Immune (ACIU) had its "buy" rating reaffirmed by BTIG Research. They now have a $8.00 price target on the stock.MarketBeat
- AC Immune (ACIU) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..MarketBeat
- AC Immune GAAP EPS of -CHF0.70, revenue of CHF3.57M [Seeking Alpha]Seeking Alpha
ACIU
Earnings
- 3/13/26 - Miss
ACIU
Sec Filings
- 3/20/26 - Form 3
- 3/18/26 - Form 3
- 3/18/26 - Form 3
- ACIU's page on the SEC website